Sitemap | Contact Us  

Welcome To Taj Pharmaceuticals Ltd API      

About Worldwide  |     FAQs    |    Careers     | |        Media Center  |  |    Taj Pharmaceuticals  World   | |     TAJ Group 

       2004 - 2019 Taj Pharmaceuticals Limited . All rights reserved

medical   Researchers

      India              Latin America/ Caribbean            Africa & Middle East              Asia              Russia              Europe  

Active Pharmaceutical Ingredients  TAJ PHARMACEUTICALS LIMITED

Quetiapine Fumarate Manufacturers in India Suppliers Quetiapine Fumarate Dossage Exporters Distributors Quetiapine Fumarate api active pharmaceuticals ingredients Quetiapine Fumarate manufacturers Side Effects bulk drugs raw material Dossage Quetiapine Fumarate companies Side Effects Dossage Importers Quetiapine Fumarate Dossage Quetiapine Fumarate Exporters Quetiapine Fumarate exporters Dossage FDA Dossage Quetiapine Fumarate Dossage DMF Symptoms Dossage Generic Taj Pharmaceuticals Ltd.

Pharmaceuticals API Manufacturer Quetiapine Fumarate, Quetiapine Fumarate manufacturer India, Quetiapine Fumarate product, Quetiapine Fumarate products, Api preparation, Certificate of Analysis API manufacturer product, Quetiapine Fumarate anti ulcer product, Certificate of Origin COA Quetiapine Fumarate COS Quetiapine Fumarate, pharmaceutical generic, pharmaceutical drug, medical, Quetiapine Fumarate pharma healthcare, pharma patents, contract MSDS manufacturing Trader Quetiapine Fumarate pharma, generic pharma, HCL pharma MSDS pharmaceutical products, pharmaceutical formulations, generic import API, Quetiapine Fumarate expectorant Pharmaceutical GMP Method of analysis formulations manufacturer, Quetiapine Fumarate DMF drug master file pharmaceutical Anti Cancer active ingredient exporter from India, pharma Quetiapine Fumarate ingredients, api, HIV Quetiapine Fumarate, tablets, capsules, syrup & protein Quetiapine Fumarate powder, GMP of Plant api nutraceuticals, gynec products, ortho ingredients in India, oncology products, Quetiapine Fumarate gastroenterology products, buy, sell orthopaedic product, who gmp, cGMP, US FDA, Quetiapine Fumarate WHO, UKMHRA Approval

   Pharmaceuticals API List >>
   Product Development
   Product Search
   Agro Chemicals
   Custom Pharma Services
   Contact Us
Quetiapine fumarate capsul




HOME >> Pharmaceuticals API List 3 >> Quetiapine Fumarate >> Dosage

Quetiapine Fumarate CAS number 111974-69-7
Quetiapine Fumarate CAS number 111974-69-7

Acute Bipolar Mania

PO 100 mg/day in 2 divided doses on day 1; increase to 400 mg/day on day 4 in increments of up to 100 mg/day in 2 divided doses. Further dosage adjustments of up to 800 mg/day by day 6 should be in increments of no more than 200 mg/day.

PO Start with 50 mg once daily at bedtime. Increase to 100 mg on day 2, 200 mg on day 3, and 300 mg on day 4. If indicated, the dose may be increased to 400 mg on day 5 and 600 mg on day 8.
Maintenance in Bipolar I Disorder

PO Generally, in the maintenance phase, patients are continued on the same dose on which they were stabilized during dose stabilization.

PO  25 mg twice daily initially; may increase in increments of 25 to 50 mg twice daily to 3 times daily on days 2 and 3 to target range of 300 to 400 mg/day by day 4. Increase dose every 2 days by 25 to 50 mg twice daily as indicated. Therapeutic dose range is 150 to 750 mg/day.

PO  Start with 300 mg once daily, preferably in the evening. Dose increases can be made at daily intervals in increments of up to 300 mg/day. Dosages above 800 mg/day have not been evaluated.
Elderly/Hepatic Function Impairment

PO Start with 25 mg/day; increase in daily increments of 25 to 50 mg/day to an effective dose.
General Advice

* Safety of dosages higher than 800 mg/day has not been evaluated.
* Take without regard to meals. Take with food if stomach upset occurs.
* Long-term use (more than 6 wk) not evaluated. Periodically reevaluate usefulness.
* When restarting patients who have had an interval of less than 1 wk off quetiapine, resume maintenance dose. If the interval is more than 1 wk, follow initial titration period.
*  tablets should be swallowed whole and not split, chewed, or crushed.
*  should be taken without food or with a light meal (about 300 calories).
* Use immediate-release tablet for schizophrenic patients requiring less than 200 mg per dose of  during the initial titration.
* Start schizophrenic elderly patients and/or patients with hepatic function impairment on the immediate-release formulation. Dose can be incrementally increased daily. When an effective dose has been reached, the patient may switch to an equivalent total daily dose of the ER formulation.
* Schizophrenic patients currently treated with divided doses of the immediate-release formulation may be switched to equivalent total daily doses of the ER formulation taken once daily.
* Consideration should be given to a slower rate of dose titration and a lower target dose in elderly patients and in patients who are debilitated or who are predisposed to hypotension.

Information Associated with Product:
Product Enquiry Product Quotation Sample Request Place Your Order  
Product Enquiry Product Quotation Sample Request Place Your Order  

Taj pharmaceuticals API Logo

Quetiapine Fumarate

More Api at Taj Pharmaceuticals Ltd.

Quetiapine Fumarate

Quinine Sulfate

Rabeprazole Sodium


Ranitidine Hydrochloride


Rivastigmine Tartrate


Rosiglitazone Maleate


Tamsulosin HCl

Tegaserod Maleate

Terbinafine HCl

Tolterodine Tartrate









Copyright Taj Pharmaceuticals Ltd. | Privacy Policy | Terms & Conditions | Sitemap

Investor Relations    Feedback     Contact Worldwide    Sitemap

taj group logo
2004 - 2019 Taj Pharmaceuticals Limited . All rights reserved
Note:-We are committed to helping you find the right answers to your questions and concerns. However, this web site is not intended to give investment advice, promote the use of Taj Pharmaceuticals Ltd products or provide information on which to base medical treatment. If you have questions regarding any Taj Pharmaceuticals Ltd product or are experiencing a medical emergency, please consult your health care provider.
Additionally, contact information on this web site cannot be used to report adverse drug events. If you are a physician, please follow the procedures required by your country's regulations. Please choose one of the given options to contact us and we will respond to your inquiry as quickly as possible.